




Cell-penetrating peptides as carriers



Zoltán Bánóczy

Department of Organic Chemistry, ELTE, Budapest

Cellular uptake of compounds



Transporter proteins/channels


The first observations

Tat (transactivator of HIV transcription)

- Tat-86 protein
 - internalisation
 - localisation in nucleus

Frankel AD, Pabo CO. *Cell* 1988, 55, 1189-1193.

$^{48}\text{GRKKRRQRRRPPQ}^{60}$




Homeodomain of Drosophila Antennapedia protein

- goes through the membrane of nervous cells
- localisation in nucleus

Joliot A, et al. *Proc Natl Acad Sci USA* 1991, 88, 1864-1868.

$^{43}\text{RQIKIWFQNRRMKWKK}^{58}$



Cell-penetrating peptides


Short peptides - with cell-internalisation ability - can transport the covalently attached cargo (protein, ODN, PNA, drugs) into cells upto 30 kDa. The mechanism of penetration is not clear.

| Peptide | Sequence (protein) | Origin |
|--------------------------|--|---|
| Tat (48–60) | ⁴⁸ GRKKRRQRRRPPQ ⁶⁰ | HIV-1 Tat protein |
| Penetratin | ⁴³ RQIKIWFQNRRMKWKK ⁵⁸ | <i>Drosophila</i> Antennapedia protein |
| Signal sequence peptide | AAVALLPAVLLALLAP | Kaposi fibroblast growth factor (K-FGF). |
| | EILLPNNYESYKYPGMFIALSK | Kaposi fibroblast growth factor (K-FGF). |
| | VQRKRQKLMP | NF-kB p50 transkription factor |
| Hydrophobic peptides | MGLGLHLLVLAALQGA | Caïman crocodylus Ig(v) |
| | MGLGLHLLVLAALQGAKKKRKV. | chimera peptide (Ig(v)-SV40 T-antigen) |
| Virial peptides/proteins | VP22 protein | herpes simplex virus-1 |
| | ¹ AVGAIGALFLGFLGAAG ¹⁷ | HIV gp41 glikoprotein, ⁸ Met→Leu |
| | GLFEAIAGFIENGWEGMIDGGGYC | Influenza hemagglutinin, |
| Substance P | RPKPQQFFGLM | neuropeptide |
| Transportan | GWTLNSAGYLLGKINLKALAALAKKIL | chimera peptide, galanin-mastoparan |

De novo designed peptides

Oligopeptides (Lys, Arg, Orn, His)

- Hexaarginine*
- peptoid transporters**
 - distance between the Arg residues
 - distance of guanidino group




* Mitchell DJ, et al. *J. Pept. Res.* 2000, 56, 318-325.

**Wender PA, et al. *Proc. Natl. Acad. Sci. USA* 2000, 97, 13003-13008.

Oligoarginines

- hexa- and octaarginine*
- arginine tree**



* Futaki S, et al. *J. Biol. Chem.* 2001, 276, 5836-5840.

** Futaki S, et al. *Biochemistry* 2002, 41, 7925-7930.

Model peptides

- KLA model peptide[#]

KLALKLALKALKAALKLA





- Model peptide^{##}

KETWWETWWTEWSQPKKKRKV

[#] Scheller A, et al. *J. Pept. Sci.* 1999, 5, 185-194.


^{##} Morris MC, et al. *Nat. Biotechnol.* 2001, 19, 1173-1176.



Cellular uptake studies using fluorescence labelling






**Olympus CKX41 fluorescence
microscope**






BD LSR II flow cytometer



First experiments

- fluorescence microscopy
- fixation
- 4 °C
- r_n



Fluorescence detection – microscopy, flow cytometry

- without fixation
- remove the membrane bound peptides
 - digestion by trypsin
 - washing with heparin
- using inhibitors


ATP depletion: NaN_3 and deoxyglucose

endocytosis inhibitors: methyl- β -cyclodextrin
chlorpromazine,

Cellular uptake studies II.


Functional studies

- luciferase splice correction test



Lundin P. et al. *Bioconj. Chem*, 2008, 19, 2535-2542

- inhibition of the expression of luciferase



RP-HPLC with fluorescence detector

Palm C, et al. *Peptides* 2006, 27 1710-1716.


Mass spectrometry

Burlina F, et al. *Angewandte Chemie* 2005, 44, 4244-4247.

Cellular uptake studies III.

Using fluorimeter

Illien F, et al. *Sci Rep.* 2016; 6, 36938.



Mechanism of internalisation


Is there receptor?

- r_n is more effective than R_n


More than one mechanism

- endocytosis
- direct penetration above a threshold concentration



Depending on the conditions



Direct internalisation – how?




Internalisation of oligoarginines





Calpain activator conjugates

Calpains



TRENDS in Molecular Medicine

Superfamily of Ca^{2+} dependent cysteine proteases.

Ca^{2+} signal induced cleavage of specific proteins involved in signaling cascades.

In mammals m-calpain and μ -calpain are constitutively expressed in all tissues.

Perrin J.B., et al., *Int. J. Biochem. Cell Biol.* 2002, 34, 722-725.

Heterodimer of non-activated m-calpain

Strobl S., et al., *Proc. Natl. Acad. Sci. U. S. A.* 2000, 97, 588-592.

Structure of conjugates

Penetratin-Calpastatin A (C)

N-terminal

X-RQIKIWFQQNRRMKWKKC-NH₂



C-terminal

H-C**SGKSGMDAALDDLIDTLGG-NH₂**
(AcCSKPIGPDDAIDALSSDFTS-NH₂)

X-RQIKIWFQQNRRMKWKKC-NH₂




CH₂-CO-**SGKSGMDAALDDLIDTLGG-NH₂**
(SKPIGPDDAIDALSSDFTS-NH₂)

X-RQIKIWFQQNRRMKWKK**SGKSGMDAALDDLIDTLGG-NH₂**
(SKPIGPDDAIDALSSDFTS-NH₂)

X: H or Hca


Conjugates labelled by two fluorophores



$\lambda_{\text{ex}} = 360 \text{ nm}$

$\lambda_{\text{em}} = 480 \text{ nm}$

**4-(7-hydroxycoumarin-2-yl) acetic acid
(Hca)**



$\lambda_{\text{ex.}} = 490 \text{ nm}$

$\lambda_{\text{em.}} = 520 \text{ nm}$

**5-carboxyfluorescein
(Flu)**



Hca-RQIKIWFQQNRRMKWKKC-NH₂



Ac-**C**SK(Flu)PIGPDDAIDALSSDFTS-NH₂

Activation of isolated m-calpain

The effect of conjugation (c = 75 μ M)



5 mM CaCl₂

KalpA + KalpC (0.1 mM)


PenKalpA + PenKalpC amide (0.1 mM)

0.1 mM CaCl₂


PenKalpA + PenKalpC S-S (0.1 mM)

PenKalpA + PenKalpC thio (0.1 mM)


Uptake of Hca-penetratin-calpastatin peptide conjugates by COS-7 cells with (A,B) or without (C) fixation.





A) HcaPenKalpA amide



B) HcaPenKalpC thioether




C) HcaPenKalpC thioether



HcaPenCalp(Flu)C conjugate with disulfide bond

Calpain activity in COS-7 cell lysate





***Detection of intracellular calpain
activity***


Calpain substrate

A novel and optimized FRET (fluorescence resonance energy transfer) substrate was designed and prepared from the preference matrix of calpain cleavage sites.



Suitable for *in vitro* measurements: the fluorescence intensity depends only on the calpain activity.

Calpain cleavage of FRET substrate – heptaarginine conjugate




$c_{\text{substrate}} = 200 \mu\text{M}$, $c_{\text{CalpainB}} = 0.5 \mu\text{M}$
 $\lambda_{\text{ex}} = 320 \text{ nm}$, $\lambda_{\text{em}} = 480 \text{ nm}$



| Substrate | K_M (μM) | k_{cat} (s^{-1}) | k_{cat}/K_M ($\text{M}^{-1}\text{s}^{-1}$) |
|---|-------------------------|--------------------------------------|---|
| <i>DABCYL-TPLKSPPPSPR-EDANS</i> | 250 | 0.2 | 680 |
| <i>DABCYL-TPLKPPSPRE(EDANS)RRRRRRR-NH₂</i> | 40 | 0.17 | 5000 |

Penetration of FRET substrate-heptaargine conjugate and substrate peptide into COS-7 cells

a)




b)



COS7 cells were incubated for 3 h and were treated by trypsin

COS7 cells were incubated at 330 μM for 4 h

Calpain activity in cell-lysate



- A) Substrate is in lysate of S2 cell
- B) Substrate is in lysate of S2 cell overexpressing calpain
- C) LY-AMC is in lysate of S2 cell overexpressing calpain


$$c_{\text{LY-AMC}} = 1 \text{ mM or } c_{\text{substrate}} = 100 \text{ } \mu\text{M}$$

LY-AMC:


$$\lambda_{\text{ex.}} = 380 \text{ nm, } \lambda_{\text{em.}} = 460 \text{ nm}$$

Substrate:

$$\lambda_{\text{ex.}} = 320 \text{ nm, } \lambda_{\text{em.}} = 480 \text{ nm}$$




S2 cells were incubated with 150 μM substrate at 25-28°C for 20 h and were lysed.



Hippocampal slices were treated only with the 50 μM cell-penetrating substrate for 5 min.


Slices treated with the 50 μM cell-penetrating substrate for 5 min and then 5 μM A+C conjugates was mixed into the solution and incubation was followed for further 15 min. Pyramidal cell layer (empty arrows) and also in other regions (filled arrows)






***Drug-Cell penetrating peptide
conjugates***

Daunomycin



- antitumor drug used in cancer treatment
- side-effects; cardiotoxicity, immunosuppression
- development of resistance

Conjugation sites



Alkyl-hydrazine

Langer, M. et al., *J. Med. Chem.*, 2001, 44, 1341.


O-alkyl hydroxylamine

Ingallinella, P. et al., *Bioorg. Med. Chem. Lett.*, 2001, 11, 1343.


Carboxylic acids

Yamamoto, K. et al., *J. Med. Chem.*, 1972, 15, 872.

Structure of conjugates




Cytostatic effect of conjugates



- Cells were treated by the conjugates solution at concentration 2.6×10^{-4} - 10^2 μM.
- The IC₅₀ values were determined by MTT assay.


The effect of trypsin treatment




HL-60 cells were treated with the solution of conjugates ($c = 30 \mu\text{M}$, 90 min), then with/without trypsin treatment the fluorescence intensity of cells was studied by flow cytometry.

Cellular uptake by HL-60 cells

Concentration dependence



Vinblastin




vincristin
vinblastin

R₁
CHO
CH₃


- *vinca* alkaloids (vincristin, vinblastin)- bisindole alkaloids
- vinblastin is used in chemotherapy
- destroy the microtubular system
- side effects, e.g. leucopenia

Structure of conjugate




two isomers: L- or D-Trp

Cytostatic activity of conjugates




Depolymerisation of microtubular system



| | vinblastin | | 17-dezacetylvinblTrp | | 17-dezacetylvinblTrpArg ₈ -2 | | 17-dezacetylvinblTrpArg ₈ -1 | |
|------------------------------|-----------------------------|-------------------------------|----------------------------|-------------------------------|---|-------------------------------|---|-------------------------------|
| | <i>aberrant mitosis (%)</i> | <i>interfase microtubules</i> | <i>Aberant mitosis (%)</i> | <i>interfase microtubules</i> | <i>Aberant mitosis (%)</i> | <i>interfase microtubules</i> | <i>Aberant mitosis (%)</i> | <i>interfase microtubules</i> |
| <i>control</i> | 2 | normal | 2 | Normal | 2 | normal | 2 | normal |
| <i>0,25μM</i> | 100 | Depolymerised | 47 | normal | 22 | normal | n. d. | n. d. |
| <i>1μM</i> | 100 | Depolymerised | 100 | fragmented | 75 | normal | 45 | normal |
| <i>2,5μM</i> | 100 | Depolymerised | 100 | fragmented | 98 | fragmented | 75 | normal |
| <i>5μM</i> | 100 | Depolymerised | 100 | depolymerise | 100 | fragmented | 100 | normal |

Methotrexate



Well-known antitumor agent.



Antifolate. Inhibit dihydrofolate reductase and thymidylate synthase.

Important step is the polyglutamilation.

Immunosuppressive and anti-inflammatory effect.

Structure of conjugates

Our aim was to use conjugates containing free and pentaglutamylated methotrexate and cell-penetrating peptide against resistant tumor cells.



Cellular uptake of conjugates

HL-60 cells

| Compound | F _{mean} (sd) | | | Fluorescent cells % (sd) | | |
|---|------------------------|---------------|--------------|--------------------------|------------|------------|
| | 1 μ M | 10 μ M | 50 μ M | 1 μ M | 10 μ M | 50 μ M |
| Cf-Arg ₈ | 2569(35) | 185413(25267) | 259163(545) | 100 (0) | 100 (0) | 100 (0) |
| Cf-Glu ₅ -Arg ₈ | 55(2) | 493(31) | 3333(689) | 3 (0) | 92 (2) | 100 (0) |
| Cf-Glu ₅ -Gly ₃ -Arg ₉ | 335 (21) | 2881 (105) | - | 62.8 (5.2) | 100 (0) | - |
| Cf-PenC(desMet ¹²) | 4129(744) | 22421(863) | 48957(10221) | 100 (0) | 100 (0) | 100 (0) |
| Cf-Glu ₅ -Pen(desMet ¹²) | 172(27) | 3450(336) | 9646(268) | 13 (2) | 100 (0) | 100 (0) |
| Cf-Glu ₅ -Gly ₃ -Pen(desMet ¹²) | 343 (12) | 3540 (372) | - | 73.9 (2) | 100 (0) | - |

HL-60 cells were treated for 90 min. After washing and trypsin treatment the fluorescence intensity of cells was measured by flow cytometry on a BD LSR II cytometer.

Cytostatic effect of MTX-conjugates

MCF-7 and MDA-MB-231 cells

| Compounds | IC ₅₀ (sd) (μM) | |
|--|----------------------------|-------------|
| | MCF-7 | MDA-MB-231 |
| Penetratin | > 100 | > 100 |
| MTX | 0.56 (0.57) | > 100 |
| MTX-Pen(desMet ¹²) (1) | >100 | 82.5 (13.9) |
| MTX-Pen(desMet ¹²) (2) | 50.4 (34.3) | 11.9 (5.4) |
| MTX-Glu ₅ -Pen(desMet ¹²) | > 100 | 0.1 (0.1) |
| MTX-Arg ₈ | > 100 | > 100 |
| MTX-Glu ₅ -Arg ₈ | > 100 | > 100 |

MCF-7 and MDA-MB-231 cells were treated for 3 hrs at 2.56×10^{-4} – 100 μM concentration range. After 3 days at 37° C, MTT-assay was carried out. (2 parallel measurements)